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Summary 
It is well known that  synthetic peptides are able to both induce and tolerize T  cells.  We have 
examined  the  parameters  leading  either  to  priming  or  tolerance  of  CD8 +  cytotoxic  T 
lymphocytes (CTL) in vivo with a major histocompatibility complex class I (H-2 D b) binding 
peptide derived from the glycoprotein (GP aa33-41) of lymphocytic choriomeningitis virus (I.CMV). 
By varying dose, route, and frequency of LCMV GP peptide application,  we found that a single 
local subcutaneous injection of 50-500 #g peptide emulsified in incomplete Freund's adjuvant 
protected mice against LCMV infection, whereas repetitive and systemic intraperitoneal application 
of the same dose caused tolerance of LCMV-specific CTL. The peptide-induced tolerance was 
transient in euthymic mice but permanent in thymectomized mice. These findings are relevant 
for a selective use of peptides as a therapeutic approach: peptide-induced priming of T  cells for 
vaccination and peptide-mediated T  cell tolerance for intervention  in immunopathologies  and 
autoimmune  diseases. 
p roteins may serve as immunogens or tolerogens,  depending 
on  mode  of administration.  Several  factors  determine 
whether a protein induces a T  cell response or renders a T 
cell unresponsive:  amount of antigen,  route and frequency 
of application, use of adjuvants, and organization of the an- 
tigen (1-3). Since T cells recognize endogeneously processed 
peptides presented by MHC class I or class II molecules (4-7), 
the question arises whether the rules for priming and toler- 
ance induction with protein antigens also apply for synthetic 
peptides. Several reports have successfully demonstrated T cell 
immunity  induced  with  peptides  in  vivo  (8-14).  These 
findings, together with the development of methods to identify 
naturally processed peptides and to predict peptide binding 
motifs for MHC molecules (15-18),  opened up the possi- 
bility of using synthetic peptides as safe vaccines (19).  Re- 
cent reports however, have also documented that peptide an- 
tigens may be used to downregulate T cell-mediated immune 
responses (20-23). Thus, peptide-induced T cell tolerance may 
represent a tool to prevent or even treat T cell-mediated au- 
toimmune diseases (24-32). If peptides are able to induce both 
immunity and tolerance, how can T cell priming be achieved 
without inducing tolerance, and how can tolerance be estab- 
lished without activation of T  cells? We have analyzed this 
issue by using a synthetic peptide derived from the glycopro- 
tein (GP aa33-41  =  GP33 peptide) of lymphocytic chorio- 
meningitis virus (LCMV) and by varying peptide dose (1-1,000 
#g), route (i.p. versus s.c.), and frequency (single versus re- 
petitive) of application.  The aim of the study was to define 
protocols  for  peptide  applications  which  either  result  in 
priming  or tolerance of peripheral  CD8 + CTL. 
Materials and Methods 
Animals.  C57BL/6 (H-2  b) mice were purchased from the In- 
stitut for Zuchthygiene  (Tierspital Z0rich,  Switzerland).  H-2  b/d 
mice  were  obtained  by breeding  C57BL/6  (H-2  b)  mice  with 
B10.D2 (H-2  d) mice. Animals were kept under conventional con- 
ditions and used in the experiments 10-14 wk after birth. C57BL/6 
mice were thymectomized at 5-10 wk of age as described (33) and 
used 4-8 wk after thymectomy. 
Virus.  The LCMV-WE strain was originally obtained from Dr. 
F. Lehmann-Grube (Hamburg,  Germany) and was propagated in 
our laboratory on L929 fibroblast cells (34). Virus stocks were diluted 
in MEM supplemented with 2% FCS. Mice were infected i.v. with 
200 PFU of LCMV-WE. 
Peptide Treatment.  IAZMV  glycoprotein peptide GP33-41 (KAV- 
YNFATM) (35) and LCMV nucleoprotein  peptides NP 394-408 
(AIFQPQNGQFIHFYR) and NP118-126 (RPQASGVYM)  (36) 
were synthesized by a solid-phase method and purchased from Neo- 
system Laboratoire (Strasbourg, France). For technical reasons (to 
prevent dimer formation),  the original cysteine at the anchor posi- 
tion 41 in the LCMV glycoprotein peptide was replaced by methi- 
onine. For injections, peptides were dissolved in HBSS and given 
either i.v. or i.p. in a total volume of 200/A or emulsified 1:1 (vol/vol) 
in IFA ( Difco Laboratories, Detroit, MI) and injected either s.c. 
at the base of the tail or i.p. in a total volume of 200 #1. Repetitive 
peptide injections were done at 3-d intervals. 
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tide immunization protocols as indicated. 10 d after the last pep- 
tide  administration,  mice were  challenged  i.v. with  200  PFU  ,---, 
LCMV-WE and the virus titer in the spleen was determined 4 d  t-  O  6 
later as described in detail (37).  __O 
Cytotoxicity Assay.  Single spleen cell suspensions from mice in-  O. 
fected with LCMV-WE 8 d before testing were prepared in corn- 
'  4 
plete MEM.  The cytolytic activity was determined in a SlCr re-  I~ 
lease assay as described (38). Briefly, fibroblast target cells MC57G  tl) 
(H-2  b) and D2 (H-2  d) were coated with LCMV peptides GP33-  O. 
41, NP394-408, or NPl18-126 at a concentration of 10-6 M, and  "i  2 
were labeled with 250/~Ci SlCr for 2 h at 37~  on a rocking plat- 
form. Target cells were washed three times and counted. 104 target  tq 
cells were incubated in 96-well round-bottom plates with spleen  O 
effector cells at ratios of 70:1, 23:1, 8:1, and 3:1 in a final volume  v-- 
of 200 #l. After a 5-h incubation period at 37~  70-1xl supernatants 
were harvested and assayed. Spontaneous release was always <20%.  .OO  8 
O 
> 
O 
_.! 
~.esu|ts 
Peptide-induced Priming of LCMV-specific CTL.  The prim- 
ing capacity of the LCMV GP33 peptide was examined in 
a  virus  protection  assay:  C57BL/6  mice  (H-2  b)  were im- 
munized once or repetitively with different doses of GP33 
peptide in IFA by different routes (s.c. versus i.p.).  10 d after 
the last peptide application, mice were challenged with I.CMV, 
and 4  d later, LCMV titers in the spleen were determined. 
Infection of naive C57BL/6 mice with 200 PFU LCMV caused 
a high virus titer (>107 PFU/g spleen), whereas mice previ- 
ously (>30 d) infected with LCMV were able to rapidly clear 
virus upon a second LCMV infection (virus titer below de- 
tection level:  <500  PFU/g  spleen).  Mice injected once s.c. 
with 50-500/zg of GP33 peptide emulsified in IFA exhibited 
low virus titer (103 PFU/g)  comparable to LCMV-primed 
memory mice (Fig.  1 A). In contrast,  a single i.p. injection 
of GP33  peptide  in  IFA  caused  only moderate  protection 
(105 PFU/g) despite the high dose of peptide (250-500 #g) 
injected  (Fig.  1 B). 
In a second experiment,  the GP33 peptide was given to 
C57BL/6 mice three times at 3-d intervals either s.c. or i.p. 
(Fig.  1, C  and D). Subcutaneous application of 3  x  50/xg 
GP33  peptide  yielded  complete  protection  (103 PFU/g). 
With increasing peptide doses, however, protection vanished 
(Fig.  1 C).  In contrast,  mice treated  three times i.p.  with 
GP33 peptide were not protected against LCMV at any close 
of peptide  tested (Fig.  1 D). 
Peptide-induced Tolerance of CTL.  Failure to induce pro- 
tection with repetitive i.p.  administration  of GP33 peptide 
suggested that peptide treatment caused tolerance of GP33- 
specific CTL. To test this, the LCMV-specific CTL activities 
of peptide-treated mice were determined 8 d after LCMV in- 
fection. LCMV-infected control C57BL/6  mice, pretreated 
with IFA only, were able to generate CTL specific for target 
cells loaded either with  the GP33 or NP394 peptide  (Fig. 
2, far left panels). The LCMV nucleoprotein peptide NP394- 
408 (NP394 peptide) is an additional CTL epitope in H-2  b 
mice that allowed us to control the specificity of GP33 pep- 
tide-induced tolerance. As shown in Fig. 2, mice treated three 
times i.p. with 50-500/~g of GP33 peptide in IFA failed to 
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Figure  1.  Parameters  defining peptide-induced  priming or tolerance  of 
CTL. C57BL/6 mice were immunized with different amounts of GP33 
peptide emulsified in IFA once s.c. (A) or i.p. (B) or three times at 3-d 
intervals s.c. (C) or i.p. (D). 10 d after the last peptide administration, 
mice were challenged i.v. with 200 PFU LCMV-WE, and virus titer in 
the spleen was analyzed 4 d later. Dots represent values from individual 
mice (five  animals per group). Detection level  is indicated as a dotted line. 
mount a GP33-specific CTL response after LCMV infection. 
In contrast, the NP394-specific CTL response was not affected 
by the GP33 peptide treatment.  Thus,  tolerance induction 
in vivo was  specific and  not  caused by an unspecific toxic 
or general immunosuppressive effect of the GP33 peptide ap- 
plication. As indicated in Fig. 2, the minimal amount of GP33 
peptide required for tolerance induction by i.p. administra- 
tion ranged between  1 and  50/zg. 
To evaluate the time dependence of peptide-induced toler- 
ance, the LCMV GP33-specific CTL response was determined 
in peptide-pretreated mice (3  x  200/zg GP33 peptide/IFA; 
i.p.) at different time points after the treatment  with pep- 
tide. As shown in Fig. 3 A, the GP33-specific CTL response 
was  virtually  absent  in  peptide-treated  mice ~<3  wk  after 
tolerization. Afterwards, however, tolerance vanished and 7 
wk after peptide treatment,  the GP33-specific CTL activi- 
ties were comparable to controls. Thus, peptide-induced CTL 
tolerance was complete but transient in normal euthymic mice. 
In contrast, thymectomized mice exhibited no GP33-specific 
CTL response, even 30 wk after peptide treatment  (Fig.  3 
B).  This finding indicates  that  the loss of tolerance in eu- 
thymic mice was due to the generation of"new" GP33-specific 
CTL in the thymus when the in vivo concentration of GP33 
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Figure  2.  Peptide-induced tolerance of CTL. C57BL/6 mice were treated 
three times at 3-d intervals with 1-500/~g GP33 peptide in IFA i.p. or 
with IFA alone. Lines represent individual animals. 10 d after the last pep- 
tide application, mice were infected i.v. with 200 PFU LCMV-WE,  and 
the ex vivo CTL activities of splenocytes were assayed 8 d later in a 51Cr 
release  assay.  MC57G  fibroblast  target  cells  were  either  loaded  with 
10 -6 M  GP33 peptide (O) or with  10 -6 M  NP394 peptide (A) or left 
untreated (O). 
peptide had dropped below a certain threshold. It further re- 
veals that neither induction nor maintenance of the GP33 
peptide-induced CTL tolerance depends upon the thymus. 
Role of Adjuvants in Induction of CTL Tolerance.  To define 
the role of adjuvants (IFA) in tolerance induction, a tolero- 
genic dose of GP33 peptide (500/xg) was administered three 
times at 3-d intervals i.v. or i.p. without IFA (Fig. 4, B and 
C). In both cases, the GP33-specific CTL response was not 
reduced 8 d after LCMV infection, when compared to BSS- 
treated control animals (Fig. 4 A). In contrast, mice treated 
three times with 500/xg GP33 peptide emulsified in IFA ex- 
hibited no GP33-specific CTL activity (Fig. 4 D). Tolerance 
induction without adjuvants was only achieved when high 
amounts (>500/~g)  of GP33 peptide were coadministered 
i.v. and i.p. (data not shown). The adjuvants most likely caused 
a slow release and prevented rapid degradation of the pep- 
tide,  thereby prolonging its half-life in vivo. 
Specific CTL  Tolerance Induced by NP118 Peptide or GP33 
Peptide.  To demonstrate that peptide-induced CTL tolerance 
was not a special feature of GP33 peptide, the LCMV-specific 
CTL response of (C57BL/6  x  B10.D2)F1  mice was exam- 
ined.  These  mice  are  able  to  develop  an  H-2b-restricted 
GP33-specific  and an H-2d-restricted NP118-specific  CTL 
response after LCMV infection. H-2  b/d Ft mice were treated 
i.p. three times at 3-d intervals with GP33 peptide (500/xg) 
or with NPl18 peptide (500/zg). IFA-treated control animals 
showed high CTL activities against both H-2  b target cells 
loaded with GP33 peptide and H-2  d target cells loaded with 
NPl18 peptide (Fig. 5 A). Mice injected with GP33 peptide 
did not develop a GP33-specific CTL response, whereas the 
NP118-specific CTL response was within normal ranges (Fig. 
5 B). Correspondingly, the NP118-specific  CTL activity in 
NPl18 peptide-treated mice was strongly reduced, whereas 
the GP33-specific  CTL activity was not diminished (Fig.  5 
C). Thus, the ability of a MHC class I binding peptide to 
tolerize T  cells is demonstrated for two independent cases. 
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Figure  3.  Peptide-induced T cell tolerance is transient 
in euthymic mice. (A) C57BL/6 mice, injected i.p. three 
times at 3-d intervals with 200/xg GP33 peptide/IFA 
or IFA alone, were infected i.v. with 200 PFU LCMV-WE 
at different time points after the last peptide applica- 
tion. Primary CTL activities of splenocytes were deter- 
mined at the indicated weeks after tolerance induction 
on MC57G target cells loaded with 10-6 M GP33 pep- 
tide (O).  (B) Thymectomized (Tx) mice were treated 
the same way-and were challenged with LCMV 30 wk 
later. 
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Figure  4.  Role of adjuvants in inducing tolerance. C57BL/6 mice  were 
injected three times at 3-d intervals with 200/~1 BSS (A) or with 500 
/zg of free GP33 peptide dissolved in BSS i.v. (B) or i.p. (C). Another 
group of mice was treated i.p. with 500/~g of GP33 peptide emulsified 
in IFA (D). 10 d after the last peptide injection, mice were challenged 
i.v. with 200 PFU LCMV-WE and primary CTL activities of splenocytes 
were determined 8 d later. MC57G target cells were left untreated (O) 
or loaded with 10 -6 M GP33 peptide (e). 
Discussion 
In the present report, we have defined protocols for peptide- 
mediated T  cell priming  or tolerance:  50-500 #g of GP33 
peptide injected once s.c. generated a protective CTL response 
without inducing tolerance (Fig.  1 A), whereas the same dose 
of the same peptide administered three times i.p.  tolerized 
the specific CTL without evidence of an immunizing effect 
(Fig.  1 D). How can these opposing effects of peptide injec- 
tion  on T  cells be explained? 
Subcutaneous application of peptide in IFA generates an 
antigen  depot  from where the peptide  slowly reaches  the 
draining lymph nodes. There peptide-loaded professional APCs 
are able to induce optimal T cell activation by providing both 
TCR engagement and costimulatory signal (39, 40). The slow 
release of peptide from a local depot (41), probably together 
with inflammatory reactions in the skin caused by the injec- 
tion procedure, may represent additional factors for optimal 
T cell priming. Once su~ciently activated, increased numbers 
of peptide-specific T cells may leave the regional lymph nodes 
and circulate  through  the body. 
In marked contrast,  when administered intraperitoneally 
or when high amounts (3  x  500-1000 #g) of GP33 peptide 
mice pretreated  with: 
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Figure 5.  Specific  CTL tolerance induced by NPll8 peptide or GP33 
peptide. (C57BL/6 x  B10.D2)F1 mice were treated i.p. three times at 
3-d intervals with either IFA (.4) or 500/~g GP33 peptide in IFA (B) or 
500/~g NP118 peptide in IFA (C). 10 d after the last peptide application, 
mice were infected i.v. with 200 PFU LCMV-WE and CTL activities of 
splenocytes were tested on GP33-1oaded (O) or unloaded (O) MC57G 
(H-2  b) or on NPll8-1oaded (&) or unloaded (A) D2 (H-2  d) target calls. 
were injected s.c., the peptide is distributed throughout the 
whole body. Thus,  most if not all peptide-specific T  cells 
are triggered via their TCR by neighboring cells that are not 
exclusively professional APCs and therefore may not provoke 
costimulation (42). When given the peptide systemically, it 
is likely that activated T  cells reencounter antigen in form 
of peptide-coated cells within a short time after initial trig- 
gering. Since T cells that are in cell cycle undergo apoptosis 
after TCR-mediated stimulation (43), one could imagine that 
most peptide-activated T  cells may succumb to activation- 
induced  cell  death  when  the  peptide  antigen  is  present 
ubiquitously. Alternatively, peptides given systemically and 
repetitively may induce virtually all  specific  T  cells  to be- 
come terminally differentiated effector T  cells that will die 
within, a few days  (44,  45).  Thus,  lack of costimulation, 
activation-induced cell death, and exhaustion may contribute 
to  peptide-induced  peripheral  expansion  and  deletion  of 
peptide-specific T cells, as observed in TCR transgenic mice 
(22,  46-48). 
Our findings hold implications for the design of peptide 
therapies  to  induce  CTL  for  vaccination  against  tumors 
(49-51) and infectious agents (9, 52-54) or to downregulate 
CTL activities in T cell-dependent diseases (27, 32). The study 
provides  the  experimental  framework  to  separate  the  im- 
munogenic and tolerogenic effect of peptide administration 
on CD8 + CTL in vivo. 
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